# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

A. 510(k) Number: K172254   
B. Purpose for Submission: To obtain a substantial equivalence determ   
C. Measurand: Anti-Borrelia burgdorferi (IgM) antibodies   
D. Type of Test: Enzyme Immunoassay   
E. Applicant: Immco Diagnostics   
F. Proprietary and Established Names: Lyme B. burgdorferi (IgM) MarStripe Test

# G. Regulatory Information:

1. Regulation section: 21 CFR 866.3830; Treponema pallidum treponemal test reagents

2. Classification: Class II

3. Product code: LSR; Reagent, Borrelia Serological Reagent

4. Panel: Microbiology

# H. Intended Use:

1. Intended use(s):

Lyme B. burgdorferi (IgM) MarStripe Test is an immunoblot assay for the in vitro qualitative detection of human IgM antibody to individual proteins of Borrelia burgdorferi in human serum or plasma $\mathrm { K } _ { 2 }$ -EDTA) in samples which have been found positive or equivocal using an EIA or IFA test procedure to provide supportive evidence of infection with B. burgdorferi.

2. Indication(s) for use: Same as Intended Use

3. Special conditions for use statement(s): For prescription use only

4. Special instrument requirements: Not applicable (N/A)

# I. Device Description:

The kit is an immunoblot method to detect IgM antibodies against B. burgdorferi antigens. The test kit contains:

Test strips. Purified B. burgdorferi antigens (3) and quality control lines (3) on nitrocellulose arepresent in specific positions • Diluent. Provided for specimen dilutions Positive Control Negative Control Conjugate. IgM-HRP Conjugate binds reactive antibodies to the Substrate Substrate. Provides colorimetric reaction for visual read of bound antibodies Wash Buffer. Removes reagents and unbound antibodies after incubation steps

# J. Substantial Equivalence Information:

1. Predicate device name(s): MarDx B. burgdorferi IgM MarBlot Strip Test System   
2. Predicate 510(k) number(s): K951709

<table><tr><td rowspan=1 colspan=1>Parameter</td><td rowspan=1 colspan=1>New deviceLyme B. burgdorferi (IgM)MarStripe Test</td><td rowspan=1 colspan=1>Predicate deviceMarDx B. burgdorferi IgMMarBlot Strip Test System(K951709)</td></tr><tr><td rowspan=1 colspan=1>Similarities</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Lyme B. burgdorferi (IgM)MarStripe Test is an immunoblotassay for the in vitro qualitativedetection of human IgM antibodyto individual proteins of Borreliaburgdorferi in human serum orplasma (K2-EDTA) in sampleswhich have been found positive orequivocal using an EIA or IFAtest procedure to providesupportive evidence of infectionwith B. burgdorferi.</td><td rowspan=1 colspan=1>MarDx B. burgdorferi (IgM)MarBlot Strip Test System is aimmunoblot assay for the in vitroqualitative detection of human IgMantibody to individual proteins ofBorrelia burgdorferi in humanserum or plasma (K2-EDTA) insamples which have been foundpositive or equivocal using an EIAor IFA test procedure to providesupportive evidence of infectionwith B. burgdorferi.</td></tr><tr><td rowspan=1 colspan=1>Detection of antibodies</td><td rowspan=1 colspan=1>3 antibodies directed againstBorrelia burgdorferi IgMantigens associated with Lymedisease</td><td rowspan=1 colspan=1>3 antibodies directed againstBorrelia burgdorferi IgMantigens associated with Lymedisease</td></tr><tr><td rowspan=1 colspan=1>Quantitation</td><td rowspan=1 colspan=1>Qualitative</td><td rowspan=1 colspan=1>Qualitative</td></tr><tr><td rowspan=1 colspan=1>Component set</td><td rowspan=1 colspan=1>Includes B. burgdorferi MarStripetest strips, B. burgdorferi IgMPositive Control, B. burgdorferiNegative Control, Conjugate(Anti- Human IgM), Substrate,Diluent and Wash Buffer</td><td rowspan=1 colspan=1>Includes B. burgdorferi Marblotstrips, B. burgdorferi WB IgMSerum Band Locator, B.burgdorferi WB Weakly ReactiveIgM Control, B. burgdorferiNegative Control, AlkalinePhosphatase Conjugate (Anti-Human IgM), Alkaline PhosphataseDeveloping Solution, 10x SampleDiluent Wash Solution</td></tr><tr><td rowspan=1 colspan=1>Positive control</td><td rowspan=1 colspan=1>Anti- B. burgdorferi IgM antibodies</td><td rowspan=1 colspan=1>Anti- B. burgdorferi IgM antibodies</td></tr><tr><td rowspan=1 colspan=1>Screening dilution</td><td rowspan=1 colspan=1>1:101</td><td rowspan=1 colspan=1>1:101</td></tr><tr><td rowspan=1 colspan=1>Reading</td><td rowspan=1 colspan=1>Visual</td><td rowspan=1 colspan=1>Visual</td></tr><tr><td rowspan=1 colspan=1>Storage</td><td rowspan=1 colspan=1>2-8°C</td><td rowspan=1 colspan=1>2-8°</td></tr><tr><td rowspan=1 colspan=1>Calibrators</td><td rowspan=1 colspan=1>Single control</td><td rowspan=1 colspan=1>Single control</td></tr><tr><td rowspan=1 colspan=1>EY</td><td rowspan=1 colspan=1>EY</td><td rowspan=1 colspan=1>EY</td></tr><tr><td rowspan=1 colspan=1>Differences</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Methodology</td><td rowspan=1 colspan=1>ImmunoBlot/LIA</td><td rowspan=1 colspan=1>ImmunoBlot/Western blot</td></tr><tr><td rowspan=1 colspan=1>Conjugate</td><td rowspan=1 colspan=1>Horseradish peroxidase</td><td rowspan=1 colspan=1>Alkaline Phosphatase</td></tr><tr><td rowspan=1 colspan=1>Substrate/Chromogen</td><td rowspan=1 colspan=1>Tetramethylbenzidine (TMB)</td><td rowspan=1 colspan=1>BCIP/NBT</td></tr><tr><td rowspan=1 colspan=1>Cutoff</td><td rowspan=1 colspan=1>Cutoff Control line</td><td rowspan=1 colspan=1>41kD band of Weakly ReactiveControl Strip</td></tr><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>Serum or Plasma</td><td rowspan=1 colspan=1>Serum</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

FDA Guidance for Industry and Food and Drug Administration Staff - Establishing the Performance Characteristics of In Vitro Diagnostic Devices for the Detection of Antibodies to Borrelia burgdorferi, published July, 2013.

CLSI M34-A: Western Blot Assay for Antibodies to Borrelia burgdorferi

CLSI EP05-A3: Evaluation of Precision of Quantitative Measurement Procedures

CLSI EP12-A2: User Protocol for Evaluation of Qualitative Test Performance

CLSI EP7-A2: Interference Testing in Clinical Chemistry

CLSI EP9-A2: Method Comparison Bias Estimation Using Patient Samples

# L. Test Principle:

Enzyme Immunoassay

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

Precision. A panel of eight specimens were tested. Each specimen was tested in 4 replicates on each run, two runs per day over 12 days for a total of 96 tests for each specimen. Samples were selected based on FDA cleared B. burgdorferi ELISA results, including 2 low negative samples, 2 high negative samples, 1 cutoff sample, 1 low positive sample and 2 moderate positive samples. The cutoff specimen presented reactions near the cutoff control for two bands.

Qualitative agreement was $100 \%$ for the results of seven specimens; the cutoff specimen produced a positive result in 78/96 replicates $( 8 1 . 3 \% )$ . A summary of results by antibody line is provided in Table 1below:

Table 1. Summary of Precision Results by Antibody Line   

<table><tr><td colspan="2">Sample 1</td><td rowspan="5"></td><td colspan="3"></td></tr><tr><td>Low Negative Band Type</td><td>EIA Value 0.22</td><td>A</td><td>a</td><td>2</td></tr><tr><td>Positives</td><td></td><td>Neg. 0 96</td><td>Neg. 0</td><td>Neg. 0</td></tr><tr><td>Ne atives % Positive Low Negative</td><td>0.20</td><td>0.0%</td><td>96 0.0%</td><td>96 0.0%</td></tr><tr><td>2 Band Type</td><td></td><td>Neg.</td><td>Neg.</td><td>Neg.</td></tr><tr><td rowspan="4">3</td><td>Positives Negatives</td><td></td><td>0</td><td>0</td><td>3</td></tr><tr><td></td><td></td><td>96</td><td>96</td><td>93</td></tr><tr><td>% Positive High Negative</td><td>0.80</td><td>0.0%</td><td>0.0%</td><td>3.1%</td></tr><tr><td>Band Type</td><td></td><td></td><td>Neg.</td><td>Neg.</td></tr><tr><td rowspan="4">4</td><td> Positives</td><td></td><td>Neg. 0</td><td>0</td><td>0</td></tr><tr><td>Negatives</td><td></td><td>96</td><td>96</td><td>96</td></tr><tr><td>% Positive</td><td></td><td>0.0%</td><td>0.0%</td><td>0.0%</td></tr><tr><td>High Negative</td><td>0.87</td><td></td><td></td><td></td></tr><tr><td rowspan="4">5</td><td>Band Type</td><td></td><td>Neg.</td><td>Neg.</td><td>Cut.</td></tr><tr><td>Positives</td><td></td><td>0</td><td>0</td><td>3</td></tr><tr><td>NNegatives</td><td></td><td>96</td><td>96</td><td>93</td></tr><tr><td>% Positive Low Positive</td><td>1.31</td><td>0.0%</td><td>0.0%</td><td>3.1%</td></tr><tr><td rowspan="4"></td><td>Band Type</td><td></td><td>Pos.</td><td>Neg.</td><td>Pos.</td></tr><tr><td>Positives</td><td></td><td>96</td><td>0</td><td>96</td></tr><tr><td>Neatives</td><td></td><td>0 100.0%</td><td>96</td><td>0</td></tr><tr><td>% Positive Cutoff</td><td>1.37</td><td></td><td>0.0%</td><td>100.0%</td></tr><tr><td></td><td>Band Type</td><td></td><td>Cut.</td><td>Neg.</td><td>Wpos.</td></tr><tr><td rowspan="4">7</td><td>Positives N Negatives</td><td></td><td>88</td><td>0</td><td>79</td></tr><tr><td></td><td></td><td>8</td><td>96</td><td>17</td></tr><tr><td>% Positive</td><td></td><td>91.7%</td><td>0.0%</td><td>82.3%</td></tr><tr><td>Moderate Positive Band Type</td><td>3.36</td><td>Pos.</td><td>Neg.</td><td>Pos.</td></tr><tr><td>8</td><td>Positives Ngatives</td><td></td><td>96</td><td>0</td><td>96</td></tr><tr><td rowspan="4"></td><td>% Positive</td><td></td><td>0 100.0%</td><td>96</td><td>0</td></tr><tr><td>Moderate Positive</td><td>2.92</td><td></td><td>0.0%</td><td>100.0%</td></tr><tr><td>Band Type</td><td></td><td>Pos.</td><td>Pos.</td><td>Pos.</td></tr><tr><td>Positives N Negatives % Positive</td><td></td><td>96 0 100.0%</td><td>96 0</td><td>96 0</td></tr></table>

Pos = positive band. ${ \overline { { \mathrm { N e g } } } } =$ negative band. Wpos $=$ weak positive band. Cut $=$ equivocal band.

Reproducibility. A panel of eight specimens was tested at three laboratories (2 external, 1 internal). At each site, each specimen was tested in 4 replicates per run, two runs per day over 12 days for a total of 288 tests. Results were read by 2 human operators at each site, equaling a total of 576 read-outs. Samples were selected based on FDA cleared B. burgdorferi ELISA results The cutoff specimen was chosen so that two bands were near the cutoff control.

Final positive or negative agreement was $100 \%$ for both low negative samples, one high negative and one moderate positive sample. One high negative sample produced a $9 9 . 7 \%$ negative agreement. One low positive and one moderate positive sample produced a $9 9 . 3 \%$ positive agreement. The cut off sample produced a $6 8 . 4 \%$ positive agreement. A summary of results by antibody line is provided in Table 2 below.

Table 2. Summary of Reproducibility Results by Antibody Line   

<table><tr><td colspan="2">Sample</td><td rowspan="2">EIA Value</td><td colspan="3"></td></tr><tr><td>1 Low Negative</td><td>0.22</td><td></td><td>2</td><td>2</td></tr><tr><td rowspan="5">2</td><td>Band Type</td><td></td><td>Neg. 0</td><td>Neg. 0</td><td>Neg.</td></tr><tr><td>Positives Negatives</td><td></td><td>576</td><td>576</td><td>1 575</td></tr><tr><td>% Positive</td><td></td><td></td><td></td><td></td></tr><tr><td>Low Negative</td><td>0.20</td><td>0.0%</td><td>0.0%</td><td>0.2%</td></tr><tr><td>Band Type</td><td></td><td>Neg.</td><td>Neg.</td><td>Neg.</td></tr><tr><td rowspan="4">3</td><td>Positives</td><td></td><td>0 576</td><td>0 576</td><td>26</td></tr><tr><td>Negatives</td><td></td><td></td><td></td><td>550</td></tr><tr><td>% Positive High Negative</td><td>0.80</td><td>0.0%</td><td>0.0%</td><td>4.5%</td></tr><tr><td>Ban Type</td><td></td><td>Neg.</td><td>Neg.</td><td>Neg.</td></tr><tr><td rowspan="5">4</td><td>Positives Negatives</td><td></td><td>0 576</td><td>0 576</td><td>0 576</td></tr><tr><td>% Positive</td><td></td><td></td><td></td><td></td></tr><tr><td>High Negative</td><td>0.87</td><td>0.0%</td><td>0.0%</td><td>0.0%</td></tr><tr><td>Band Type</td><td></td><td>Neg.</td><td>Neg.</td><td>Cut.</td></tr><tr><td>Positives Negatives</td><td></td><td>1 575</td><td>2 574</td><td>58 518</td></tr><tr><td rowspan="4">5</td><td>% Positive</td><td>1.31</td><td>0.2%</td><td>0.3%</td><td>10.1%</td></tr><tr><td>Low Positive</td><td></td><td></td><td></td><td></td></tr><tr><td>Band Type Positives</td><td></td><td>Pos. 572</td><td>Neg. 0</td><td>Pos. 576</td></tr><tr><td>Negatives</td><td></td><td>4</td><td>576</td><td>0</td></tr><tr><td rowspan="4">6</td><td>% Positive Cutoff</td><td>1.37</td><td>99.3%</td><td>0.0%</td><td>100.0%</td></tr><tr><td>Band Type</td><td></td><td></td><td>Neg.</td><td></td></tr><tr><td>Positives</td><td></td><td>Cut. 442</td><td>0</td><td>WPos. 504</td></tr><tr><td>Negatives</td><td></td><td>134</td><td>576</td><td>72</td></tr><tr><td rowspan="4">7</td><td>% Positive</td><td></td><td>76.7%</td><td>0.0%</td><td>87.5%</td></tr><tr><td>Moderate Positive*</td><td>3.36</td><td></td><td></td><td></td></tr><tr><td>Band Type Positives</td><td></td><td>Pos. 573</td><td>Neg. 0</td><td>Pos. 572</td></tr><tr><td>Negatives</td><td></td><td>1</td><td>574</td><td>2</td></tr><tr><td rowspan="8">8</td><td>% Positive</td><td></td><td>99.8%</td><td>0.0%</td><td>99.7%</td></tr><tr><td>Moderate Positive Band Type</td><td>2.92</td><td></td><td></td><td></td></tr><tr><td>Positives</td><td></td><td>Pos.</td><td>Pos.</td><td>Pos.</td></tr><tr><td></td><td></td><td>576</td><td>572</td><td>576</td></tr><tr><td>Negatives</td><td></td><td>0</td><td>4</td><td>0</td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td>% Positive</td><td></td><td>100.0%</td><td>99.3%</td><td>100.0%</td></tr></table>

\* Two replicates of this run are missing due to lack of sample.

b. Linearity/assay reportable range: Not applicable (N/A) c. Traceability, Stability, Expected values (controls, calibrators, or methods): N/A

# d. Detection limit: N/A

# e. Analytical specificity:

Sera from 220 normal individuals, with no history of physician-diagnosed Lyme disease representing endemic and non-endemic geographic regions of the United States were tested with the Lyme $B .$ . burgdorferi (IgM) Marstripe Test. Analytical specificity was deterermined to be $9 9 . 5 \%$ ( $9 5 \%$ CI: $9 7 . 1 \% - 1 0 0 \% )$ . See Tables 3 and 4 below.

Table 3. Analytical Specificity Results by Band   

<table><tr><td rowspan=1 colspan=2>Specimen</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>p41</td><td rowspan=1 colspan=1>p39</td><td rowspan=1 colspan=1>p23</td></tr><tr><td rowspan=1 colspan=1>Normal Individuals</td><td rowspan=1 colspan=1>n%</td><td rowspan=1 colspan=1>220</td><td rowspan=1 colspan=1>10.5%</td><td rowspan=1 colspan=1>20.9%</td><td rowspan=1 colspan=1>10.5%</td><td rowspan=1 colspan=1>41.8%</td></tr></table>

Table 4. Analytical Specificity Results   

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=1>Population</td></tr><tr><td rowspan=1 colspan=1>Normal Indivduals</td></tr><tr><td rowspan=3 colspan=1>Lyme IgMMarStripeTest</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>219</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>220</td></tr></table>

# Cross-Reactivity:

A total of 136 potentially cross-reactive specimens from individuals with other autoimmune disorders or infectious conditions, including Ehrlichia chafeensis (10), Babesia microti (10), Leptospira interrogans (10), Helicobacter pylori (10), Syphilis (10), Influenza (10), Rocky Mountain spotted fever (10), parvovirus B19 (9), CMV (10) systemic lupus erythematosus (15), rheumatoid arthritis (16), and celiac disease (16) were tested. Positive results and breakdown of antibody reactions by line are provided below in Table 5.

Table 5. Cross-Reactivity Results by Antibody Band   

<table><tr><td rowspan=1 colspan=2>EY</td><td rowspan=1 colspan=4>Positive specimens/reactive antibody lines - n(%)</td></tr><tr><td rowspan=1 colspan=1>Population</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>p41</td><td rowspan=1 colspan=1>p39</td><td rowspan=1 colspan=1>p23</td></tr><tr><td rowspan=1 colspan=1>E. chafeensis</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>3 (30)*</td><td rowspan=1 colspan=1>3 (30)</td><td rowspan=1 colspan=1>5 (50)</td><td rowspan=1 colspan=1>4 (40)</td></tr><tr><td rowspan=1 colspan=1>B. microti</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>2 (20)*</td><td rowspan=1 colspan=1>2 (20)</td><td rowspan=1 colspan=1>1 (10)</td><td rowspan=1 colspan=1>1 (10)</td></tr><tr><td rowspan=1 colspan=1>L. interogans</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>1 (10)*</td><td rowspan=1 colspan=1>1 (10)</td><td rowspan=1 colspan=1>1 (10)</td><td rowspan=1 colspan=1>1 (10)</td></tr><tr><td rowspan=1 colspan=1>H. pylori</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>1 (1)*</td><td rowspan=1 colspan=1>1 (1)</td><td rowspan=1 colspan=1>1 (1)</td><td rowspan=1 colspan=1>1 (1)</td></tr><tr><td rowspan=1 colspan=1>Syphilis</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0 (0)</td><td rowspan=1 colspan=1>0 (0)</td><td rowspan=1 colspan=1>0 (0)</td><td rowspan=1 colspan=1>0 (0)</td></tr><tr><td rowspan=1 colspan=1>Influenza</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0 (0)</td><td rowspan=1 colspan=1>0 (0)</td><td rowspan=1 colspan=1>1 (10)</td><td rowspan=1 colspan=1>0 (0)</td></tr><tr><td rowspan=1 colspan=1>Epstein-Barr Virus</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>0 (0)</td><td rowspan=1 colspan=1>1 (4.5)</td><td rowspan=1 colspan=1>0 (0)</td><td rowspan=1 colspan=1>0 (0)</td></tr><tr><td rowspan=1 colspan=1>Rocky Mountain Spotted fever</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0 (0)</td><td rowspan=1 colspan=1>0 (0)</td><td rowspan=1 colspan=1>0 (0)</td><td rowspan=1 colspan=1>0 (0)</td></tr><tr><td rowspan=1 colspan=1>Parvovirus B19</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>0 (0)</td><td rowspan=1 colspan=1>0 (0)</td><td rowspan=1 colspan=1>2 (22.2)</td><td rowspan=1 colspan=1>1 (11.1)</td></tr><tr><td rowspan=1 colspan=1>Systmatic lupus erythematosus</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>0 (0)</td><td rowspan=1 colspan=1>0 (0)</td><td rowspan=1 colspan=1>0 (0)</td><td rowspan=1 colspan=1>0 (0)</td></tr><tr><td rowspan=1 colspan=1>Cytomegalovirus</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0 (0)</td><td rowspan=1 colspan=1>0 (0)</td><td rowspan=1 colspan=1>0 (0)</td><td rowspan=1 colspan=1>0 (0)</td></tr><tr><td rowspan=1 colspan=1>Rheumatoid arthritis</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>0 (0)</td><td rowspan=1 colspan=1>0 (0)</td><td rowspan=1 colspan=1>0 (0)</td><td rowspan=1 colspan=1>0 (0)</td></tr><tr><td rowspan=1 colspan=1>Celiac disease</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>0 (0)</td><td rowspan=1 colspan=1>0 (0)</td><td rowspan=1 colspan=1>0 (0)</td><td rowspan=1 colspan=1>0 (0)</td></tr></table>

\* Positive results were also observed with an FDA cleared western blot

# Interferences:

Five (5) specimens (2 negative, 3 positive) were spiked with hemoglobin $( 2 \mathrm { g } / \mathrm { L } )$ , unconjugated bilirubin $( 3 4 2 \mu \mathrm { m o l / L } )$ , rheumatoid factor $( 1 0 0 \mathrm { I U / m l } )$ , triglycerides $( 3 . 7 \mathrm { m m o l / L } )$ and total cholesterol $\mathrm { 1 3 \ m m o l / L }$ ), and then tested for Borrelia burgdorferi IgM following guidance of CLSI EP7-A2. Samples were tested with and without interfering agents. Qualitative agreement between results, spiked and unspiked was $100 \%$ for all interferents tested.

# f. Assay cut-off:

Cut-off was established by testing a panel of Lyme positive specimens along with healthy normal and controls. The Cut-Off Control Line was derived from these studies and provides a qualitative visual reference point for determination of bands as positive or negative.

2. Comparison studies:

a. Method comparison with predicate device:

# Prospective Study:

Specimens that were determined positive using an FDA cleared first-step EIA assay were tested prospectively at three geographically distinct study sites. The specimens testing positive $\scriptstyle ( \ n = 6 7 6 )$ on a FDA cleared first-step EIA were tested with Lyme B. burgdorferi (IgM) MarStripe Test and an FDA cleared immunoblot. Interpretation of immunoblot results followed the recommended criteria described by the Centers for Disease Control (CDC) and the Second National Conference on Serological Diagnosis of Lyme Disease. The results are summarized below in Table 6.

Table 6. Results of Lyme B. burgdorferi (IgM) MarStripe Test and Predicate – Prospective Specimens   

<table><tr><td rowspan="2" colspan="2"></td><td colspan="3">FDA Cleared Immunoblot</td></tr><tr><td>Positive</td><td>Negative</td><td>Total</td></tr><tr><td rowspan="3">Lyme IgM MarStripe Test</td><td>Positive</td><td>302</td><td>23</td><td>325</td></tr><tr><td>Negative</td><td>21</td><td>330</td><td>351</td></tr><tr><td>Total</td><td>323</td><td>353</td><td>676</td></tr></table>

Positive Percent Agreement: $9 3 . 5 \%$ $9 5 \%$ CI: $9 0 . 1 \% - 9 5 . 8 \% )$ Negative Percent Agreement: $9 3 . 5 \%$ b $9 5 \%$ CI: $9 0 . 2 \% - 9 5 . 7 \% )$

# b. Matrix comparison:

To establish equivalence of serum vs. plasma matrices, 20 pairs of sera/plasma (samples A-J below) were sourced from specimens tested on an FDA cleared Lyme EIA assay. These specimens included 3 Western Blot IgM positives and 17 negatives. These samples were assayed on the Lyme B. burgdorferi (IgM) MarStripe Test. AQL was $100 \%$ agreement between serum and plasma. See Table 7 below for results.

Table7. Serum vs. Plasma – Matrix Comparisson Study   

<table><tr><td colspan="1" rowspan="1">SampleID</td><td colspan="1" rowspan="1">Type</td><td colspan="1" rowspan="1">p41*</td><td colspan="1" rowspan="1">p39*</td><td colspan="1" rowspan="1">p23*</td><td colspan="1" rowspan="1">Result</td><td colspan="1" rowspan="1">Band %Pos Agrmt**</td><td colspan="1" rowspan="1">Band %Neg** Agrmt</td></tr><tr><td colspan="1" rowspan="1">A</td><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">NEG</td><td colspan="1" rowspan="2">100</td><td colspan="1" rowspan="2">100</td></tr><tr><td colspan="1" rowspan="1">A</td><td colspan="1" rowspan="1">Plasma</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">B</td><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="2">100</td><td colspan="1" rowspan="2">100</td></tr><tr><td colspan="1" rowspan="1">B</td><td colspan="1" rowspan="1">Plasma</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">POS</td></tr><tr><td colspan="1" rowspan="1">C</td><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">NEG</td><td colspan="1" rowspan="2">100</td><td colspan="1" rowspan="2">100</td></tr><tr><td colspan="1" rowspan="1">C</td><td colspan="1" rowspan="1">Plasma</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">D</td><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">NEG</td><td colspan="1" rowspan="2">100</td><td colspan="1" rowspan="2">100</td></tr><tr><td colspan="1" rowspan="1">D</td><td colspan="1" rowspan="1">Plasma</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">E</td><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="2">100</td><td colspan="1" rowspan="2">100</td></tr><tr><td colspan="1" rowspan="1">E</td><td colspan="1" rowspan="1">Plasma</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">POS</td></tr><tr><td colspan="1" rowspan="1">F</td><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">NEG</td><td colspan="1" rowspan="2">100</td><td colspan="1" rowspan="2">100</td></tr><tr><td colspan="1" rowspan="1">F</td><td colspan="1" rowspan="1">Plasma</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">G</td><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">NEG</td><td colspan="1" rowspan="2">100</td><td colspan="1" rowspan="2">100</td></tr><tr><td colspan="1" rowspan="1">G</td><td colspan="1" rowspan="1">Plasma</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">H</td><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">NEG</td><td colspan="1" rowspan="2">100</td><td colspan="1" rowspan="2">100</td></tr><tr><td colspan="1" rowspan="1">H</td><td colspan="1" rowspan="1">Plasma</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">I</td><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">NEG</td><td colspan="1" rowspan="2">100</td><td colspan="1" rowspan="2">100</td></tr><tr><td colspan="1" rowspan="1">I</td><td colspan="1" rowspan="1">Plasma</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">J</td><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="2">100</td><td colspan="1" rowspan="2">100</td></tr><tr><td colspan="1" rowspan="1">J</td><td colspan="1" rowspan="1">Plasma</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">POS</td></tr><tr><td colspan="1" rowspan="1">K</td><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">NEG</td><td colspan="1" rowspan="2">100</td><td colspan="1" rowspan="2">100</td></tr><tr><td colspan="1" rowspan="1">K</td><td colspan="1" rowspan="1">Plasma</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">SampleID</td><td colspan="1" rowspan="1">Type</td><td colspan="1" rowspan="1">p41*</td><td colspan="1" rowspan="1">p39*</td><td colspan="1" rowspan="1">p23*</td><td colspan="1" rowspan="1">Result</td><td colspan="1" rowspan="1">Band %Pos Agrmt**</td><td colspan="1" rowspan="1">Band %Neg**Agrmt</td></tr><tr><td colspan="1" rowspan="1">L</td><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">NEG</td><td colspan="1" rowspan="2">100</td><td colspan="1" rowspan="2">100</td></tr><tr><td colspan="1" rowspan="1">L</td><td colspan="1" rowspan="1">Plasma</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">M</td><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">NEG</td><td colspan="1" rowspan="2">100</td><td colspan="1" rowspan="2">100</td></tr><tr><td colspan="1" rowspan="1">M</td><td colspan="1" rowspan="1">Plasma</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">N</td><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">NEG</td><td colspan="1" rowspan="2">100</td><td colspan="1" rowspan="2">100</td></tr><tr><td colspan="1" rowspan="1">N</td><td colspan="1" rowspan="1">Plasma</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">NEG</td><td colspan="1" rowspan="2">100</td><td colspan="1" rowspan="2">100</td></tr><tr><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">Plasma</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">P</td><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">NEG</td><td colspan="1" rowspan="2">100</td><td colspan="1" rowspan="2">100</td></tr><tr><td colspan="1" rowspan="1">P</td><td colspan="1" rowspan="1">Plasma</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Q</td><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">NEG</td><td colspan="1" rowspan="2">100</td><td colspan="1" rowspan="2">100</td></tr><tr><td colspan="1" rowspan="1">Q</td><td colspan="1" rowspan="1">Plasma</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">R</td><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">NEG</td><td colspan="1" rowspan="2">100</td><td colspan="1" rowspan="2">100</td></tr><tr><td colspan="1" rowspan="1">R</td><td colspan="1" rowspan="1">Plasma</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">S</td><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">NEG</td><td colspan="1" rowspan="2">100</td><td colspan="1" rowspan="2">100</td></tr><tr><td colspan="1" rowspan="1">S</td><td colspan="1" rowspan="1">Plasma</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">T</td><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">NEG</td><td colspan="1" rowspan="2">100</td><td colspan="1" rowspan="2">100</td></tr><tr><td colspan="1" rowspan="1">T</td><td colspan="1" rowspan="1">Plasma</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">NEG</td></tr></table>

$^ { * } 0 =$ negative band result, $1 =$ positive band result \*\*Refers to agreement across all three bands

3. Clinical studies:

a. Clinical Sensitivity:

87 well characterized Lyme disease clinical specimens were tested with the Lyme $B$ . burgdorferi (IgM) MarStripe Test. Specimens included samples from early, early disseminated, and late phases of the disease. The performance of the Lyme $B$ . burgdorferi (IgM) MarStripe Test was compared with that of an FDA cleared device.

Table 8. Lyme B.burgdorferi (IgM) MarStripe Test and Predicate Results for WellCharacterized Samples   

<table><tr><td rowspan=2 colspan=1>Interval</td><td rowspan=2 colspan=1>n</td><td rowspan=1 colspan=2>Lyme IgM MarStripe</td><td rowspan=1 colspan=2>FDA cleared IgM WB</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>%</td></tr><tr><td rowspan=1 colspan=1>Early Lyme (stage 1)</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>42.1</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>47.4</td></tr><tr><td rowspan=1 colspan=1>Early disseminated (stage 2)</td><td rowspan=1 colspan=1>43</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>11.6</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>14</td></tr><tr><td rowspan=1 colspan=1>Late Lyme (stage 3)</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>8</td></tr><tr><td rowspan=1 colspan=1>Overall</td><td rowspan=1 colspan=1>87</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>18.4</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>19.5</td></tr></table>

# Sensitivity Comparison:

Lyme $B$ . burgdorferi (IgM) MarStripe Test: $1 8 . 4 \%$ (16/87) ( $9 5 \%$ CI: 11.2% ‐ 28.4%) Predicate device: $1 9 . 5 \%$ (17/87) ( $9 5 \%$ CI: $1 2 . 1 \% - 2 9 . 7 \% )$

CDC Panel Testing: A reference panel from the Center for Disease Control and Prevention (Lyme Disease Validation Panel $\mathrm { n } { = } 1 0$ , Lyme Disease Basic Research Panel $\mathtt { n } = 3 2$ ) was tested with the Lyme $B _ { \cdot }$ . burgdorferi (IgM) MarStripe Test and the predicate device.

Table 9. Lyme B.burgdorferi (IgM) MarStripe Test and Predicate Results for CDC Panel   

<table><tr><td rowspan=2 colspan=1>Interval</td><td rowspan=2 colspan=1>n</td><td rowspan=1 colspan=2>Lyme IgM MarStripe Test</td><td rowspan=1 colspan=2>Predicate IgM WB</td></tr><tr><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>%</td></tr><tr><td rowspan=1 colspan=1>Controls</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>8</td></tr><tr><td rowspan=1 colspan=1>Early Lyme (stage 1)</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>60</td></tr><tr><td rowspan=1 colspan=1>Early disseminated (stage 2)</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>Late Lyme (stage 3)</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>50</td></tr><tr><td rowspan=1 colspan=1>Overall</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>23.8</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>31.0</td></tr></table>

Note: The results are presented as a means to convey further information on the performance of this assay with a masked, characterized serum panel. This does not imply an endorsement of the assay by the CDC.

b. Clinical specificity: N/A

c. Other clinical supportive data (when a. and b. are not applicable): N/A

4. Clinical cut-off: N/A

5. Expected Values/Reference range:

The performance of the Lyme B. burgdorferi (IgM) MarStripe Test was evaluated in clinical studies using sera obtained from the following: 1) patients meeting a case definition for Lyme disease based on physician diagnosis, B. burgdorferi culture, and other laboratory tests; 2) patients for whom requests were made for routine $B .$ . burgdorferi serology tests; and 3) apparently healthy individuals from endemic and non-endemic regions for Lyme disease.

The first table summarizes the presence of B. burgdorferi specific bands in specimens from documented cases of Lyme disease. Specimens have been grouped by the time after onset of symptoms.

Table 10. Lyme B. burgdorferi (IgM) MarStripe Test results in defined Lyme disease populations   

<table><tr><td rowspan=2 colspan=1>Disease Stage</td><td rowspan=2 colspan=1></td><td rowspan=1 colspan=5>MarStripe Results</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>p41</td><td rowspan=1 colspan=1>p39</td><td rowspan=1 colspan=1>p23</td></tr><tr><td rowspan=2 colspan=1>Early Lyme, Stage 1</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>9</td></tr><tr><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>42.1%</td><td rowspan=1 colspan=1>47.4%</td><td rowspan=1 colspan=1>36.8%</td><td rowspan=1 colspan=1>47.4%</td></tr><tr><td rowspan=2 colspan=1>Early disseminated, Stage 2</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>43</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>10</td></tr><tr><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>11.6%</td><td rowspan=1 colspan=1>18.6%</td><td rowspan=1 colspan=1>14.0%</td><td rowspan=1 colspan=1>23.3%</td></tr><tr><td rowspan=2 colspan=1>Late Lyme, Stage 3</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>5</td></tr><tr><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>12.0%</td><td rowspan=1 colspan=1>8.0%</td><td rowspan=1 colspan=1>8.0%</td><td rowspan=1 colspan=1>20.0%</td></tr></table>

Table 11. Lyme B. burgdorferi (IgM) MarStripe Test results in the prospective study   

<table><tr><td rowspan=2 colspan=1>Specimen</td><td rowspan=2 colspan=1>−</td><td rowspan=1 colspan=5>MarStripe Results</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>p41</td><td rowspan=1 colspan=1>p39</td><td rowspan=1 colspan=1>p23</td></tr><tr><td rowspan=2 colspan=1>Lyme EIA positive / equivocalspecimens</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>676</td><td rowspan=1 colspan=1>325</td><td rowspan=1 colspan=1>362</td><td rowspan=1 colspan=1>218</td><td rowspan=1 colspan=1>365</td></tr><tr><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>48.1%</td><td rowspan=1 colspan=1>53.6%</td><td rowspan=1 colspan=1>32.2%</td><td rowspan=1 colspan=1>54.0%</td></tr></table>

Table 12. Lyme B. burgdorferi (IgM) MarStripe Test results in healthy normal individuals   

<table><tr><td rowspan=2 colspan=1>Specimen</td><td rowspan=2 colspan=1></td><td rowspan=1 colspan=5>MarStripe Results</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>p41</td><td rowspan=1 colspan=1>p39</td><td rowspan=1 colspan=1>p23</td></tr><tr><td rowspan=2 colspan=1>Normal individuals</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>220</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>4</td></tr><tr><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>0.5%</td><td rowspan=1 colspan=1>0.9%</td><td rowspan=1 colspan=1>0.5%</td><td rowspan=1 colspan=1>1.8%</td></tr></table>

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.